Rudolph M Navari1, Marie C Brenner. 1. Department of Medicine, Indiana University School of Medicine South Bend, IN, USA. navari.1@nd.edu
Abstract
PURPOSE: The purpose of the study was to determine the effectiveness of megestrol acetate (MA) and olanzapine (OLN) for the treatment of cancer-related anorexia (CRA). METHODS:Eighty adult patients with advanced gastrointestinal cancer or lung cancer (stages III and IV) with CRA (loss of appetite and greater than or equal to 5% loss of preillness stable weight) were randomized to receive daily MA or MA plus OLN for a period of 8 weeks. Patients were assessed weekly using the M.D. Anderson Symptom Inventory with specific measurement of weight, appetite, nausea, and quality of life (QOL) measures. RESULTS: For the 37 patients receiving MA, 15 patients had a greater than or equal to 5% weight gain, 2 patients had an appetite improvement, 3 patients had an improvement in nausea, and 5 patients had an improvement in QOL at both 4 and 8 weeks. For the 39 patients receivingMA plus OLN, 33 patients had a greater than or equal to 5% weight gain, 25 patients had an appetite improvement, 21 patients had an improvement in nausea, and 23 patients had an improvement in QOL at both 4 and 8 weeks, and there was an improvement in general activity, mood, work, walking, and enjoyment at 8 weeks. There were no grade III or IV treatment-related toxicities in patients receiving MA or the combination of MA plus OLN. CONCLUSIONS: The combination of MA and OLN appears to be an effective intervention for patients with CRA.
RCT Entities:
PURPOSE: The purpose of the study was to determine the effectiveness of megestrol acetate (MA) and olanzapine (OLN) for the treatment of cancer-related anorexia (CRA). METHODS: Eighty adult patients with advanced gastrointestinal cancer or lung cancer (stages III and IV) with CRA (loss of appetite and greater than or equal to 5% loss of preillness stable weight) were randomized to receive daily MA or MA plus OLN for a period of 8 weeks. Patients were assessed weekly using the M.D. Anderson Symptom Inventory with specific measurement of weight, appetite, nausea, and quality of life (QOL) measures. RESULTS: For the 37 patients receiving MA, 15 patients had a greater than or equal to 5% weight gain, 2 patients had an appetite improvement, 3 patients had an improvement in nausea, and 5 patients had an improvement in QOL at both 4 and 8 weeks. For the 39 patients receiving MA plus OLN, 33 patients had a greater than or equal to 5% weight gain, 25 patients had an appetite improvement, 21 patients had an improvement in nausea, and 23 patients had an improvement in QOL at both 4 and 8 weeks, and there was an improvement in general activity, mood, work, walking, and enjoyment at 8 weeks. There were no grade III or IV treatment-related toxicities in patients receiving MA or the combination of MA plus OLN. CONCLUSIONS: The combination of MA and OLN appears to be an effective intervention for patients with CRA.
Authors: F P Bymaster; J F Falcone; D Bauzon; J S Kennedy; K Schenck; N W DeLapp; M L Cohen Journal: Eur J Pharmacol Date: 2001-11-02 Impact factor: 4.432
Authors: Rudolph M Navari; Lawrence H Einhorn; Steven D Passik; Patrick J Loehrer; Cynthia Johnson; M L Mayer; J McClean; Jake Vinson; W Pletcher Journal: Support Care Cancer Date: 2005-02-08 Impact factor: 3.603
Authors: N Sarhill; F Mahmoud; D Walsh; K A Nelson; S Komurcu; M Davis; S LeGrand; O Abdullah; L Rybicki Journal: Support Care Cancer Date: 2003-08-15 Impact factor: 3.603
Authors: Carlo Pirri; Evan Bayliss; James Trotter; Ian N Olver; Paul Katris; Peter Drummond; Robert Bennett Journal: Support Care Cancer Date: 2012-09-14 Impact factor: 3.603
Authors: Sally Wheelwright; Anne-Sophie Darlington; Jane B Hopkinson; Deborah Fitzsimmons; Alice White; Colin D Johnson Journal: Support Care Cancer Date: 2013-06-25 Impact factor: 3.603
Authors: Rudolph M Navari; Cameron M Pywell; Jennifer G Le-Rademacher; Patrick White; Andrew B Dodge; Costantine Albany; Charles L Loprinzi Journal: JAMA Oncol Date: 2020-06-01 Impact factor: 31.777